Susquehanna International Group
DMTX

Susquehanna International Group’s Dimension Therapeutics, Inc DMTX Stock Holding History

Susquehanna International Group’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22,767
Closed -$33K – 10362
2017
Q2 		$33K Buy
22,767
+11,359
+100% +$15.4K ﹤0.01% 8966
2017
Q1 		$20K Sell
11,408
-8,670
-43% -$23K ﹤0.01% 8731
2016
Q4 		$87K Buy
+20,078
New +$107K ﹤0.01% 9142

Other funds holding DMTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Susquehanna International Group's DMTX Position: Q3 2017 in Review

Susquehanna International Group sold out of Dimension Therapeutics, Inc (DMTX) in Q3 2017, closing a stake of 22,767 shares — an estimated $33K sold.

Susquehanna International Group first reported a position in DMTX in Q4 2016 and held it in 3 quarters. The position peaked at $87K in Q4 2016. 34 funds tracked by Wall St. Rank hold DMTX as of Q3 2017.

  • Susquehanna International Group reported no remaining Dimension Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
  • Susquehanna International Group sold 22,767 Dimension Therapeutics, Inc shares in Q3 2017, an estimated $33K.
  • Susquehanna International Group first reported a position in Dimension Therapeutics, Inc in Q4 2016 and held it in 3 quarters.
  • Susquehanna International Group's Dimension Therapeutics, Inc position peaked at $87K in Q4 2016.
  • 34 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q3 2017.

Based on Susquehanna International Group's 13F filing for Q3 2017, filed 14 Nov 2017.